Table 2 Discovery set: cell cycle SNPs and ovarian cancer risk (P<0.05)

From: Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis

  Samples** Log-additive Heterozygote Homozygote rare allele P -values
Gene/SNP ID Cases Controls OR (95% CI) OR (95% CI) OR (95% CI) Log-additive Dominant Recessive
ABL1
rs2855192 825 940 1.26 (1.03–1.55) 1.14 (0.90–1.44) 2.81 (1.29–6.09) 0.02 0.09 0.01
CCNB2
 rs1486878 829 939 1.14 (0.98–1.33) 1.04 (0.85–1.27) 1.53 (1.06–2.21) 0.08 0.31 0.04
CCND3
 rs3218086 827 941 1.23 (1.03–1.47) 1.18 (0.95–1.47) 1.75 (1.01–3.03) 0.02 0.05 0.07
CDKN1A
 rs7767246 826 941 0.83 (0.69–0.99) 0.83 (0.67–1.02) 0.69 (0.40–1.20) 0.04 0.04 0.28
CDC2
 rs2448343 828 935 0.91 (0.79–1.05) 1.13 (0.91–1.39) 0.71 (0.52–0.97) 0.20 0.88 0.01
CDK2
 rs2069414 821 930 1.36 (1.03–1.78) 1.36 (1.02–1.81) 1.70 (0.27–10.83) 0.03 0.03 0.60
CDK7
 Rs12656449 828 941 1.02 (0.8–1.29) 0.86 (0.66–1.13) 2.91 (1.08–7.86) 0.90 0.61 0.03
E2F2
 rs3218203 827 941 1.12 (0.95–1.32) 1.01 (1.08–1.25) 1.62 (1.02–2.59) 0.18 0.47 0.04
 rs760607 824 941 0.87 (0.75–1.00) 0.78 (0.63–0.97) 0.81 (0.60–1.08) 0.05 0.02 0.57
E2F3
 rs7760528 828 940 0.86 (0.75–1.00) 0.93 (0.75–1.14) 0.69 (0.50–0.97) 0.05 0.18 0.04
 rs2328524 829 941 0.88 (0.76–1.01) 0.83 (0.67–1.02) 0.79 (0.59–1.07) 0.06 0.05 0.35
  1. Multivariate logistic hormone replacement therapy, parity and body mass index; P-values <0.05 are in bold type, as are CIs that exclude 1.0.